Table 1 Costing assumptions
From: Examining the unit costs of COVID-19 vaccine delivery in Kenya
Estimate | Data Source | |
|---|---|---|
Demographics | ||
Target adult population-over 18 years (2021) | 26,781,011 | 2019 census report [7] |
Population growth rate | 2.2% | 2019 census report [12] |
Vaccine coverage | ||
30% coverage | 17% of vaccines procured by government 83% of vaccines procured by COVAX and through bilateral negotiations | Assumption: Vaccines procured by COVAX and through bilateral negotiations cover 20% and 5% of the population, regardless of vaccination strategy |
50% coverage | 50% of vaccines procured by government 50% of vaccines procured by COVAX and through bilateral negotiations | |
70% coverage | 64% of vaccines procured by government 36% of vaccines procured by COVAX and through bilateral negotiations | |
100% coverage | 75% of vaccines procured by government 25% of vaccines procured by COVAX and through bilateral negotiations | |
Vaccine and related supplies characteristics | ||
Vaccine wastage rate | 10% | [13] |
Syringes wastage rates | 10% | Interview with national level official |
Number of doses on schedule | 2 doses per person | |
Add-on vaccine procurement costs | ||
Freight and insurance fees | 3.0% | Program reports |
Handling fees | 4.0% | |
Clearance charges | 0.1% | |
Import declaration fees | 2.0% | |
Railway development levy | 3.5% | |